Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients with Impaired Glucose Tolerance: The STOP-NIDDM Trial

JAMA

Volumn 290, Issue 4, 2003, Pages 486-494

  Chiasson, Jean Louis ^a   Josse, Robert G ^b   Gomis, Ramon ^c   Hanefeld, Markolf ^d   Karasik, Avraham ^e   Laakso, Markku ^f  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF BARCELONA   (Spain)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e SHEBA MEDICAL CENTER   (Israel)

^f UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; PLACEBO; ALPHA GLUCOSIDASE; ANTIDIABETIC AGENT;

ABDOMINAL PAIN; ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; FLATULENCE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME; BLOOD; DIABETIC ANGIOPATHY; DRUG ANTAGONISM; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; POSTPRANDIAL STATE; RISK; RISK FACTOR;

ACARBOSE; ALPHA-GLUCOSIDASES; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; RISK; RISK FACTORS;

EID: 0038455703     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.4.486     Document Type: Article

References (48)

1. de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes: the Verona Diabetes Study. Diabetes Care. 1999;22:756-761.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
3. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med. 1991;151:1141-1147.
4. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999;48:937-942.
5. U.K. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care. 1997;20:1683-1687.
6. Hypertension in Diabetes Study (HDS), I: Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens. 1993;11:309-317.
7. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233-240.
8. Glucose tolerance and cardiovascular mortality comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397-405.
9. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39:1577-1583.
10. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. JAMA. 1990;263:2893-2998.
11. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance: the Whitehall Study. Lancet. 1980;1:1373-1376.
12. Fontbonne A, Eschwège E, Cambien F, et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Diabetologia. 1989;32:300-304.
13. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care. 1979;2:131-141.
14. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care. 1999;22:920-924.
15. Barzilay JI, Spiekerman CF, Wahl PW, et al. Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet. 1999;354:622-625.
16. 1C level. Diabetes Care. 2000;23:1830-1834.
17. Bonora E, Kiechl S, Oberhollenzer F, et al. Impaired glucose tolerance, type II diabetes mellitus, and carotid atherosclerosis: prospective results from the Bruneck Study. Diabetologia. 2000;43:156-164.
18. O'Leary DH, Polak JF, Kronmal RA, et al. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study: the CHS Collaborative Research Group. Stroke. 1992; 23:1752-1760.
19. Yamasaki Y, Kawamori R, Matsushima H, et al. Asymptomatic hyperglycaemia is associated with increased intimal plus medial thickness of the carotid artery. Diabetologia. 1995;38:585-591.
20. Beks PH, Mackaay AJ, De Vries H, De Neeling JN, Bouter LM, Heine RJ. Carotid artery stenosis is related to blood glucose level in an elderly Caucasian population: the Hoorn Study. Diabetologia. 1997;40: 290-298.
21. Hanefeld M, Koehler C, Schaper F, et al. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis. 1999;144:229-235.
22. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072-2077.
23. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M, for the STOP-NIDDM trial. An international study on the efficacy of an α-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Diabetes Care. 1998;21: 1720-1725.
24. World Health Oganization. Definition, Diagnosis, and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. Part I: Diagnosis and Classification of Diabetes Mellitus. Geneva, Switzerland: World Health Organization; 1999.
25. Sobey WJ, Beer SF, Carrington CA, et al. Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins. Biochem J. 1989;260:535-541.
26. 2+ precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin Chem. 1982; 28:1379-1388.
27. Friedwald WT, Levy RJ, Frederickson DS. Estimation of concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
28. Haffner SM, American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care. 2003;26(suppl 1):S83-S86.
29. De Vegt F, Dekker JM, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. Similar 9-year mortality risks and reproducibility for the World Health Organization and American Diabetes Association glucose tolerance categories: the Hoorn Study. Diabetes Care. 2000;23: 40-44.
30. Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL. Postchallenge hyperglycemia and mortality in a national sample of US adults. Diabetes Care. 2001;24:1397-1402.
31. Hamman RF, Marshall JA, Baxter J, et al. Methods and prevalence of non-insulin-dependent diabetes mellitus in a biethnic Colorado population. Am J Epidemiol. 1989;129:295-311.
32. Haffner SM, Valdez R, Morales PA, Mitchell BD, Hazuda HP, Stern MP. Greater effect of glycemia on incidence of hypertension in women than in men. Diabetes Care. 1992;15:1277-1284.
33. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37:1053-1059.
34. Després JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis. 1990;10:497-511.
35. Despres JP, Tremblay A, Theriault G, Perusse L, Leblanc C, Bouchard C. Relationships between body fatness, adipose tissue distribution and blood pressure in men and women. J Clin Epidemiol. 1988;41:889-897.
36. Laakso M, Lehto S, Penttilä I, Pyörälä K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in ptaients with non-insulin-dependent diabetes. Circulation. 1993;88(pt 1):1421-1430.
37. Göke B, Herrmann C, Göke R, et al. Intestinal effects of α-glucosidase inhibitors: absorption of nutrients and enterohormonal changes. Eur J Clin Invest. 1994;24(suppl 3):25-30.
38. Seifarth C, Begmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to α-glucosidase inhibition (acarbose) in type 2 diabetic patients. Diabetic Med. 1998;15:485-491.
39. Chiasson JL, Josse RG, Leiter LA, et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care. 1996;19: 1190-1193.
40. Ceriello A, Bortolotti N, Motz E, et al. Meal-generated oxidative stress in type 2 diabetic patients. Diabetes Care. 1998;21:1529-1533.
41. Ceriello A, Quagliaro L, D'Amico M, et al. Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes. 2002; 51:1076-1082.
42. Ceriello A, Mercuri F, Quagliaro L, et al. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia. 2001;44:834-838.
43. Ceriello A, Taboga C, Tonutti L, et al. Post-meal coagulation activation in diabetes mellitus: the effect of a carbose. Diabetologia. 1996;39:469-473.
44. Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest. 2001;08: 635-636.
45. Ceriello A, Bortolotti N, Falleti E, et al. Total radical-trapping antioxidant parameter in NIDDM patients. Diabetes Care. 1997;20:194-197.
46. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104:2673-2678.
47. Kawano H, Motoyama T, Hirashima O, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol. 1999;34:146-154.
48. El Midaoui A, Wu R, De Champlain J. Prevention of hypertension, hyperglycemia and vascular oxidative stress by aspirin treatment in chronically glucose-fed rats. J Hypertens. 2002;20:1407-1412